Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4180507 | 0.77 | MAPK1 (0.44) | MAPK1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5512243 | 0.77 | MAPK1 (0.46) | MAPK1MAPTALDH1A1RAB9ANPC1 | |
| SCHEMBL4802236 | 0.66 | LMNA (0.46) | ALDH1A1USP2SMN1; SMN2TSHRLMNA | |
| SCHEMBL5740508 | 0.66 | HPGD (0.34) | MAPTALDH1A1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL4175138 | 0.66 | — | — | |
| SCHEMBL8661648 | 0.65 | LMNA (0.44) | ALDH1A1USP2SMN1; SMN2TSHRLMNA | |
| SCHEMBL17233042 | 0.65 | LMNA (0.43) | MAPTALDH1A1USP2RAB9ANPC1 | |
| SCHEMBL4265054 | 0.65 | SMN1; SMN2 (0.69) | ALDH1A1RAB9ANPC1SMN1; SMN2TSHR | |
| SCHEMBL4255014 | 0.65 | SMN1; SMN2 (0.51) | ALDH1A1RAB9ANPC1SMN1; SMN2TSHR | |
| SCHEMBL23625644 | 0.64 | RAB9A (0.65) | ALDH1A1USP2RAB9ATSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137637-A1 | Tetrazolyl-Methylene Amino Acid Derivatives | PFIZER INC. (US) | 2009-05-28 | — | — | US | disclosed |
| EP-1828162-A1 | TETRAZOLYL-METHYLENE AMINO ACID DERIVATIVES | Warner-Lambert Company LLC (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006061706-A1 | TETRAZOLYL-METHYLENE AMINO ACID DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137637-A1 | Tetrazolyl-Methylene Amino Acid Derivatives | MMP13, MMP11, MMP3 | MAPK1 2026/4885MAPT 1673/4885ALDH1A1 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.